DATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGODATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGO
Home/Compounds/Albiglutide
GLP-1 agonistFDA approvedRx required

Albiglutide

Also known as: Tanzeum · Eperzan
Brands: Tanzeum · Eperzan

Long-acting GLP-1 receptor agonist (albumin fusion); commercially withdrawn in 2018 for business reasons, not safety.

A
Grade A
Multiple human RCTs
Human studies28
PubMed citations28
Routesubcutaneous
Regulatory (US)FDA approved · Rx
Last verified2 days ago

Mechanism of action

GLP-1 dimer genetically fused to human albumin. Extended half-life enables weekly dosing.

Evidence summary

28
Human studies
28
PubMed citations
25
Clinical trials
A
Evidence grade

HARMONY outcomes trial showed cardiovascular benefit. GSK withdrew commercially in 2018.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.
Administration routes
subcutaneous

Side effects & safety

No FDA label or editorial side-effect profile is on file for this compound yet. See the clinical trials and citations sections for study-reported safety data.

Interactions

No documented drug interactions on file.

Regulatory status

United States
FDA approved

FDA approved (Tanzeum) but commercially discontinued in 2018. Label remains on file.

Compounding
Not permitted

Not available via 503A/503B compounding pharmacies.

Regulatory data last verified 4/19/2026

Clinical trials

NCT05220917Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes StudyActive Not Recruiting · Cardiovascular Events · n=781430NCT07188545Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)Active Not Recruiting · Cardiovascular Kidney Metabolic Syndrome · n=23280000NCT03492580Comparison of Canagliflozin vs. Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Patients With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular DiseaseCompleted · Diabetes Mellitus, Type 2 · n=714582NCT06449235Efficacy and Safety of Omarigliptin, A Weekly Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Management: Real-World Evaluation in BangladeshNot Yet Recruiting · Phase 4 · Type2diabetes · n=938NCT02787551A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (Alone or With Pioglitazone and/or SGLT2 Inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension PeriodCompleted · Phase 3 · Type 2 Diabetes Mellitus · n=514NCT02229227Study 200977: Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine in the Treatment of Subjects With Type 2 Diabetes Mellitus: The Switch StudyCompleted · Phase 3 · Diabetes Mellitus, Type 2 · n=814NCT02846233Is the Stepping-down Approach a Better Option Than Multiple Daily Injections in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?Completed · N/A · Type 2 Diabetes Mellitus · n=22NCT02802514An Exploratory Randomized, 2-Part, Single-blind, 2-Period Crossover Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy VolunteersTerminated · Phase 4 · Diabetes Mellitus · n=5NCT02793154A Randomized, Open-label, Active-Controlled, Parallel-Group, Exploratory Study on the Effects of Repeated Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Subjects With Type 2 Diabetes MellitusTerminated · Phase 4 · Diabetes Mellitus, Type 2 · n=4NCT02284009Study 110933: Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes MellitusCompleted · Phase 2 · Diabetes Mellitus, Type 1 · n=67NCT02683746A Repeat-dose Study in Subjects With Type 2 Diabetes Mellitus to Assess the Efficacy, Safety, Tolerability and Pharmacodynamics, of Albiglutide Liquid Drug ProductCompleted · Phase 3 · Diabetes Mellitus, Type 2 · n=308NCT02750930An Open-label Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Subjects With Type 2 Diabetes MellitusTerminated · Phase 4 · Diabetes Mellitus, Type 2 · n=8

Showing 12 of 25 indexed studies. View all on ClinicalTrials.gov →

Citations

PMID 40892610Galli M, Benenati S et al. · Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients.Journal of the American College of Cardiology (2025)HumanPMID 38271596Krychtiuk KA, Marquis-Gravel G et al. · Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial.European heart journal. Cardiovascular pharmacotherapy (2024)HumanPMID 37231200García-Casares N, González-González G et al. · Effects of GLP-1 receptor agonists on neurological complications of diabetes.Reviews in endocrine & metabolic disorders (2023)HumanPMID 37701904Xie Z, Hu J et al. · Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.Frontiers in endocrinology (2023)HumanPMID 36691309Amaro A, Sugimoto D et al. · Efficacy and safety of semaglutide for weight management: evidence from the STEP program.Postgraduate medicine (2023)HumanPMID 37454782Kapoor I, Sarvepalli SM et al. · GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials.Survey of ophthalmology (2023)HumanPMID 34721294Zhang YS, Zheng YD et al. · Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.Frontiers in endocrinology (2022)HumanPMID 35217468Shetty R, Basheer FT et al. · Adverse drug reactions of GLP-1 agonists: A systematic review of case reports.Diabetes & metabolic syndrome (2022)HumanPMID 32077010Maselli DB, Camilleri M · Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity.Advances in experimental medicine and biology (2021)HumanPMID 33068776Nauck MA, Quast DR et al. · GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.Molecular metabolism (2021)HumanPMID 31422062Kristensen SL, Rørth R et al. · Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.The lancet. Diabetes & endocrinology (2020)HumanPMID 30291013Hernandez AF, Green JB et al. · Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.Lancet (London, England) (2019)HumanPMID 28050889Brønden A, Knop FK et al. · Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide.Clinical pharmacokinetics (2018)HumanPMID 25374965Muscogiuri G, Gastaldelli A · Albiglutide for the treatment of type 2 diabetes.Drugs of today (Barcelona, Spain : 1998) (2017)HumanPMID 28678550Rendell MS · The safety of albiglutide for the treatment of type 2 diabetes.Expert opinion on drug safety (2017)HumanPMID 27981757Htike ZZ, Zaccardi F et al. · Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.Diabetes, obesity & metabolism (2017)HumanPMID 26092960Davis PN, Ndefo UA et al. · Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2016)HumanPMID 25777969Blair HA, Keating GM · Albiglutide: a review of its use in patients with type 2 diabetes mellitus.Drugs (2016)HumanPMID 26276240Fisher M, Petrie MC et al. · Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.The lancet. Diabetes & endocrinology (2016)HumanPMID 26371721Shaefer CF, Kushner P et al. · User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.Postgraduate medicine (2016)Human

Showing 20 of 28 papers. View all on PubMed →